8-K current report · filed Nov 10, 2026

Arbutus Biopharma Corp (ABUS) 8-K Current Report: November 10, 2026

Item 2.02Item EX-99.1ABUS overview

Short answer

Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter financial results for period ended September 30, 2026 announced.

Arbutus Biopharma Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Third-quarter financial results for period ended September 30, 2026 announced
  • Investor-relevant details, including revenue, expenses and cash position, contained in Exhibit 99.1
  • Results provide updated view of Arbutus’s operating performance and liquidity during fiscal 2026

Item EX-99.1 · Exhibit EX-99.1

  • Cash and marketable securities $337.5M at September 30, up from $91.5M, strengthening funding for clinical programs
  • $230M tender offer repurchased 46M shares at $5.00, approximately 23% of outstanding shares, materially reducing share count
  • Q3 net income $59.1M, or $0.30 per diluted share, versus a $7.7M loss, driven primarily by $67.3M Genevant dividend income
  • FDA lifted AB-101 clinical hold, reopening U.S. development of the oral PD-L1 inhibitor
  • New Japan lawsuits and expanded Canadian claims increase potential LNP litigation recoveries, while adding enforcement costs and uncertainty

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Arbutus Biopharma Corp 8-K filings

Get the next ABUS 8-K as it lands

Follow ABUS for push alerts, or ask the research agent what this filing means.